Dr. John Byrd on Challenges in CLL

John C. Byrd, MD
Published: Monday, Jun 20, 2016



John Byrd, MD director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute discusses challenges in chronic lymphocytic leukemia (CLL).
 
Novel treatments are exciting, but unfortunately not all patients are responding, says Byrd. There is a relatively uncommon condition called Richter's syndrome, where CLL transforms into an aggressive lymphoma, which is difficult to treat. That is an area where more research is needed, says Byrd.
 
Another challenge in CLL comes from the high cost of the treatments available. Patients often can not afford the drug that is best for them due to low income, or inadequate insurance. This needs to solved, says Byrd.
 


John Byrd, MD director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute discusses challenges in chronic lymphocytic leukemia (CLL).
 
Novel treatments are exciting, but unfortunately not all patients are responding, says Byrd. There is a relatively uncommon condition called Richter's syndrome, where CLL transforms into an aggressive lymphoma, which is difficult to treat. That is an area where more research is needed, says Byrd.
 
Another challenge in CLL comes from the high cost of the treatments available. Patients often can not afford the drug that is best for them due to low income, or inadequate insurance. This needs to solved, says Byrd.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x